Equity Research Biotechnology

Should You Buy Verastem, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Verastem, Inc. (VSTM) scores 5.4/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $7.34, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 0 of 1 CirclFi valuation models project upside for Verastem, Inc. (VSTM) at $7.34 — the model consensus leans bearish, with a Quality Score of 5.4/10 and Value-Trap risk of 47/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 5.4/10 — Moderate — mixed signals
  • Value Trap Risk: 47/100 — Elevated — exercise caution
  • Fair Value Range: $2.99 – $2.99 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

5.4 /10

Moderate — mixed signals

Value Trap Risk

47 /100
Elevated

Elevated — exercise caution

Model Consensus

1 /13
Active Models

Avg. confidence: 51%

What Is the Investment Case for Verastem, Inc. (VSTM) in 2026?

What Is the Bull Case vs the Bear Case for Verastem, Inc. (VSTM)?

Bull case versus bear case for Verastem, Inc. (VSTM) at $7.34, derived from 1 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $2.99 target (-59.3%)
No active model projects meaningful upside for VSTM at $7.34. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Quality of Company (QOC) framework, Verastem, Inc.'s score of 5.4/10 signals fundamental weaknesses that could undermine the investment thesis.
According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality.
According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $2.99 (-59.3%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: competitive pipeline overlap represents a meaningful risk for Verastem, Inc. and its Biotechnology peers.

How Does VSTM Compare to Its Biotechnology Peers?

ZIVO ZIVO Bioscience, Inc
5.4
APLM Apollomics, Inc.
5.3
PULM Pulmatrix, Inc.
5.4
PHVS Pharvaris N.V.
5.3
ANEB Anebulo Pharmaceutic
5.4
NBTX Nanobiotix S.A.
5.3
SPRB Spruce Biosciences,
4.7
CTXR Citius Pharmaceutica
3.7

Valuation data pages: ZIVO · APLM · PULM · PHVS · ANEB · NBTX · SPRB · CTXR · FBIO · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like VSTM on Quality?

Closest companies to VSTM’s Quality of Company score of 5.4/10, across all industries.

Why Do CirclFi’s 1 Models Disagree on VSTM?

Spread

0%

Fair Value Range

$2.99 – $2.99

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

ML-RIV

$2.99 (-59.3%)

Most Bearish

ML-RIV

$2.99 (-59.3%)

What Are the Biggest Risks of Buying VSTM Stock?

Value Trap Warning

VT score 47/100 — apparent discount may mask decay.

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View VSTM Data Page →

So Is Verastem, Inc. (VSTM) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Verastem, Inc. at $7.34. 1/1 models flag overvaluation, median fair value sits at $2.99 (-59.3%), and the risk-reward profile appears unfavorable. Quality at 5.4/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Verastem, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About VSTM Stock?

Should I buy VSTM stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for VSTM at $7.34. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Verastem, Inc.?

Key risks include: an elevated Value Trap score of 47/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does VSTM compare to its competitors?

Among Biotechnology peers, VSTM holds a Quality Score of 5.4/10. Comparable companies include ZIVO (QOC 5.4), APLM (QOC 5.3), PULM (QOC 5.4). The relative ranking helps investors identify whether VSTM offers better fundamental quality than alternatives in the same sector.

Is VSTM a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VSTM's Quality Score of 5.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy VSTM at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $2.99 to $2.99. At $7.34, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for VSTM.

View VSTM Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →